Evidence map›Paper›PMID 36855431›Full record

ArticlePeerJ2023

High-throughput sequencing approach for the identification of lncRNA biomarkers in hepatocellular carcinoma and revealing the effect of ZFAS1/miR-150-5p on hepatocellular carcinoma progression.

Peng Zhu, Yongyan Pei, Jian Yu, Wenbin Ding, Yun Yang, Fuchen Liu, Lei Liu, Jian Huang, Shengxian Yuan, Zongyan Wang and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Peng Zhu *Department of Hepatic Surgery (III), The Third Affiliated Hospital of Naval Medical University, Shanghai, China.
Yongyan Pei *School of Chemistry and Chemical Engineering, Guangdong Pharmaceutical University, Zhongshan, Guangdong, China.
Jian YuDepartment of General Surgery, The Third Affiliated Hospital of Naval Medical University, Shanghai, China.
Wenbin DingDepartment of Hepatic Surgery (III), The Third Affiliated Hospital of Naval Medical University, Shanghai, China.
Yun YangDepartment of Hepatic Surgery (III), The Third Affiliated Hospital of Naval Medical University, Shanghai, China.
Fuchen LiuDepartment of Hepatic Surgery (III), The Third Affiliated Hospital of Naval Medical University, Shanghai, China.
Lei LiuDepartment of Hepatic Surgery (III), The Third Affiliated Hospital of Naval Medical University, Shanghai, China.
Jian HuangDepartment of Hepatic Surgery (III), The Third Affiliated Hospital of Naval Medical University, Shanghai, China.
Shengxian YuanDepartment of Hepatic Surgery (III), The Third Affiliated Hospital of Naval Medical University, Shanghai, China.
Zongyan WangDepartment of Hepatic Surgery (III), The Third Affiliated Hospital of Naval Medical University, Shanghai, China.
Fangming GuDepartment of Hepatic Surgery (III), The Third Affiliated Hospital of Naval Medical University, Shanghai, China.
Zeya PanDepartment of Hepatic Surgery (III), The Third Affiliated Hospital of Naval Medical University, Shanghai, China.
Jinzhong ChenState Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China.
Jinrong QiuDepartment of Biotherapy, The Third Affiliated Hospital of Naval Medical University, Shanghai, China.
Huiying LiuDepartment of Biotherapy, The Third Affiliated Hospital of Naval Medical University, Shanghai, China.
Fudan University · CNGuangdong Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: To screen abnormal lncRNAs and diagnostic biomarkers in the progression of hepatocellular carcinoma through high-throughput sequencing and explore the underlying mechanisms of abnormal lncRNAs in the progression of hepatocellular carcinoma. Methods: The transcriptome sequencing was used to analyze the RNA expression profile and identify differentially expressed RNAs. Hub lncRNAs were screened by combining (WGCNA, ceRNA regulatory network, PPI, GO and KEGG analyses, Kaplan-Meier curve analysis, Cox analysis, risk model construction and qPCR). Thereafter, the correlation between the expression of hub lncRNAs and tumor clinicopathological parameters was analyzed, and the hub lncRNAs were analyzed by GSEA. Finally, the effects of hub RNAs on the proliferation, migration and invasion of HepG2 cells were investigated Results: Compared with the control group, a total of 610 lncRNAs, 2,593 mRNAs and 26 miRNAs were screened in patients with hepatocellular carcinoma. Through miRNA target prediction and WGCNA, a ceRNA was constructed, comprising 324 nodes and 621 edges. Enrichment analysis showed that mRNAs in ceRNA were involved mainly in cancer development progression. Then, the ZFAS1/miR-150-5p interaction pair was screened out by Kaplan Meier curve analysis, Cox analysis and qPCR analysis. Its expression was related to tumor stage, TNM stage and patient age. ROC curve analysis showed that it has a good predictive value for the risk of hepatocellular carcinoma. GSEA showed that ZFAS1 was also enriched in the regulation of immune response, cell differentiation and proliferation. Loss-of-function experiments revealed that ZFAS1 inhibition could remarkably suppress HepG2 cell proliferation, migration and invasion Conclusion: ZFAS1 is associated with the malignant status and prognosis of patients with hepatocellular carcinoma, and the ZFAS1/miR-150-5p axis is involved in hepatocellular carcinoma progression.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsMicroRNAsRNA, Long NoncodingBiomarkersHigh-Throughput Nucleotide SequencingHumansBiomarkersMicroRNAsMIR150, humanRNA, Long NoncodingHepatocellular carcinomaLong non-coding RNAProgressionRNA sequencingZFAS1/miR-150-5p

Identifiers

PMID36855431
PMCPMC9968462
OpenAlexW4321597979

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.